The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review

Scandinavian Cardiovascular Journal

Volumn 51, Issue 5, 2017, Pages 243-247

  Ruzieh, Mohammed ^a   Batizy, Lillian ^a   Dasa, Osama ^a   Oostra, Carson ^a   Grubb, Blair ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Adrenergic antibodies; autonomic dysregulation; cholinergic antibodies; POTS

Indexed keywords

ADRENERGIC RECEPTOR; AUTOANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; CHOLINERGIC RECEPTOR;

AUTOIMMUNITY; ORTHOSTATIC INTOLERANCE; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PRIORITY JOURNAL; REVIEW; SYNDROME; ANIMAL; BLOOD PRESSURE; BODY POSITION; HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; BLOOD PRESSURE; HUMANS; ORTHOSTATIC INTOLERANCE; POSTURE; RECEPTORS, ADRENERGIC; RECEPTORS, CHOLINERGIC; RISK FACTORS;

EID: 85025826138     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/14017431.2017.1355068     Document Type: Review

References (42)

1. Fedorowski A, Melander O. Syndromes of orthostatic intolerance:a hidden danger. J Intern Med. 2013;273:322–335.
2. Grubb BP., Postural tachycardia syndrome. Circulation. 2008;117:2814–2817.
3. Li H, Yu X, Liles C, et al. Autoimmune basis for postural tachycardia syndrome. J Am Heart Assoc. 2014;3:e000755.
4. Tomljenovic L, Colafrancesco S, Perricone C, et al. Postural orthostatic tachycardia with chronic fatigue after HPV vaccination as part of the 'autoimmune/auto-inflammatory syndrome induced by adjuvants':case report and literature review. J Investig Med High Impact Case Rep. 2014;2:2324709614527812.
5. Blitshteyn S., Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol. 2014;21:135–139.
6. Kanjwal K, Karabin B, Sheikh M, et al. New onset postural orthostatic tachycardia syndrome following ablation of AV node reentrant tachycardia. J Interv Card Electrophysiol. 2010;29:53–56.
7. Dupond JL, Gil H, Bouhaddi M, et al. Acute dysautonomia secondary to autoimmune diseases:efficacy of intravenous immunoglobulin and correlation with a stimulation of plasma norepinephrine levels. Clin Exp Rheumatol. 1999;17:733–736.
8. Ishitobi M, Haginoya K, Kitamura T, et al. Acute dysautonomia:complete recovery after two courses of IVIg. Brain Dev. 2004;26:542–544.
9. Kanjwal K, Karabin B, Kanjwal Y, et al. Autonomic dysfunction presenting as postural orthostatic tachycardia syndrome in patients with multiple sclerosis. Int J Med Sci. 2010;7:62–67.
10. Blitshteyn S., Autoimmune markers and autoimmune disorders in patients with postural tachycardia syndrome (POTS). Lupus. 2015;24:1364–1369.
11. Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med. 2000;343:847–855.
12. Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome:the Mayo clinic experience. Mayo Clin Proc. 2007;82:308–313.
13. McKeon A, Lennon VA, Lachance DH, et al. Ganglionic acetylcholine receptor autoantibody:oncological, neurological, and serological accompaniments. Arch Neurol. 2009;66:735–741.
14. Cutsforth-Gregory J, Coon E, McKeon A, et al. Dysautonomia due to ganglionic nicotinic acetylcholine receptor autoimmunity (S18. 007). Neurol Clin Pract. 2016;86:S18.007.
15. Yu X, Stavrakis S, Hill MA, et al. Autoantibody activation of beta-adrenergic and muscarinic receptors contributes to an 'autoimmune' orthostatic hypotension:receptor autoantibodies in orthostatic hypotension. J Am Soc Hypertension. 2012;6:40–47.
16. Strosberg AD., Structure, function, and regulation of adrenergic receptors. Protein Sci. 1993;2:1198–1209.
17. Taylor MRG., Pharmacogenetics of the human beta-adrenergic receptors. Pharmacogenom J. 2006;7:29–37.
18. Osborn JL, DiBona GF, Thames MD., Beta-1 receptor mediation of renin secretion elicited by low-frequency renal nerve stimulation. J Pharmacol Exp Ther. 1981;216:265–269.
19. Overgaard CB, Džavík V., Inotropes and vasopressors:review of physiology and clinical use in cardiovascular disease. Circulation. 2008;118:1047–1056.
20. Kanagy Nancy L., α2-Adrenergic receptor signalling in hypertension. Clin Sci. 2005;109:431–437.
21. Philipp M, Brede M, Hein L., Physiological significance of α2-adrenergic receptor subtype diversity:one receptor is not enough. Am J Physiol Regul Integr Comp Physiol. 2002;283:R287–R295.
22. Taylor MRG, Bristow MR., The emerging pharmacogenomics of the β-adrenergic receptors. Congest Heart Fail. 2004;10:281–288.
23. Gauthier C, Tavernier G, Charpentier F, et al. Functional beta3-adrenoceptor in the human heart. J Clin Invest. 1996;98:556–562.
24. Li H, Kem DC, Reim S, et al. Agonistic autoantibodies as vasodilators in orthostatic hypotension:a new mechanism. Hypertension. 2012;59:402–408.
25. Fedorowski A, Li H, Yu X, et al. Antiadrenergic autoimmunity in postural tachycardia syndrome. Europace. 2016.
26. Lennon VA, Ermilov LG, Szurszewski JH, et al. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest. 2003;111:907–913.
27. Vernino S, Low PA, Lennon VA., Experimental autoimmune autonomic neuropathy. J Neurophysiol. 2003;90:2053–2059.
28. Sandroni P, Vernino S, Klein CM, et al. Idiopathic autonomic neuropathy:comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. Arch Neurol. 2004;61:44–48.
29. Gibbons CH, Freeman R., Antibody titers predict clinical features of autoimmune autonomic ganglionopathy. Auton Neurosci. 2009;146:8–12.
30. Wang X-L, Chai Q, Charlesworth MC, et al. Autoimmunoreactive IgGs from patients with postural orthostatic tachycardia syndrome. Prot Clin Appl. 2012;6:615–625.
31. Wallukat GNE, Morwinski R, Müller J., Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy. Herz. 2000;25:261–266.
32. Stavrakis S, Kem DC, Patterson E, et al. Opposing cardiac effects of autoantibody activation of β-adrenergic and M2 muscarinic receptors in cardiac-related diseases. Int J Cardiol. 2011;148:331–336.
33. Yu X, Patterson E, Stavrakis S, et al. Development of cardiomyopathy and atrial tachyarrhythmias associated with activating autoantibodies to beta-adrenergic and muscarinic receptors. J Am Soc Hypertension. 2009;3:133–140.
34. Magnusson Y, Wallukat G, Waagstein F, et al. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation. 1994;89:2760–2767.
35. Limas CJ, Limas C. Beta-adrenoceptor antibodies and genetics in dilated cardiomyopathy-an overview and review. Eur Heart J. 1991;12(Suppl D):175–177.
36. Wenzel KHH, Wallukat G, Derer W, et al. Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension. PLoS One. 2008;3:e3742.
37. Fu MLHH, Wallukat G, Hilme E, et al. Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension. Lancet. 1994;344:1660–1663.
38. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–1533.
39. Tsokos GC., Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–2121.
40. Gibbons CH, Vernino SA, Kaufmann H, et al. L-DOPS therapy for refractory orthostatic hypotension in autoimmune autonomic neuropathy. Neurology. 2005;65:1104–1106.
41. Modoni A, Mirabella M, Madia F, et al. Chronic autoimmune autonomic neuropathy responsive to immunosuppressive therapy. Neurology. 2007;68:161–162.
42. Gibbons CH, Vernino SA, Freeman R., Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy. Arch Neurol. 2008;65:213–217.